Patrick K. Moonan

Patrick K. Moonan

Auto-generated profile, based on publicly available information

Patrick K. Moonan

Centers for Disease Control and Prevention, Atlanta

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2008 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MHMichele C. Hlavsa
Michele C. Hlavsa
PMPatrick K. Moonan
Patrick K. Moonan
LCLauren S. Cowan
Lauren S. Cowan
TNThomas R. Navin
Thomas R. Navin
JKJ. Steve Kammerer
J. Steve Kammerer
PLPhilip A. LoBue
Philip A. LoBue
Background. Understanding the epidemiology of human Mycobacterium bovis tuberculosis (TB) in the United States is imperative; this disease can be foodborne or airborne, and current US control strategies are focused on TB due to Mycobacterium tuberculosis and airborne transmission. The National TB Genotyping Service's work has allowed systematic identification of M. tuberculosis-complex isolates and enabled the first US-wide study of M. bovis TB.

23 December 2011 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ECEleanor S. Click
Eleanor S. Click
PMPatrick K. Moonan
Patrick K. Moonan
CWCarla A. Winston
Carla A. Winston
LCLauren S. Cowan
Lauren S. Cowan
JOJohn E. Oeltmann
John E. Oeltmann
(See the Editorial Commentary by Kato-Maeda and Nahid, on pages 220–4 .) Background. Genotyping of Mycobacterium tuberculosis has revealed 4 major phylogenetic lineages with differential distribution worldwide. It is not clear whether different lineages are associated with different sites of infection (eg, pulmonary tuberculosis versus extrapulmonary tuberculosis). We sought to determine whether M. tuberculosis lineage is associated with the site of tuberculosis disease. Methods. We conducted a cross-sectional analysis of all culture-confirmed cases of tuberculosis with routinely determined M. tuberculosis spoligotype–defined lineage reported to the US National Tuberculosis Surveillance System from 2004 through 2008. Odds ratios (ORs) were used to assess the relation between disease site and M. tuberculosis lineage, after adjustment for age, sex, human immunodeficiency virus infection status, region of birth, and race/ethnicity. Results. Of 53972 reported culture-positive tuberculosis cases, 32000 (59.3%) were cases of M. tuberculosis that included complete spoligotype-based data on lineage. Of these, 23844 (74.5%) were exclusively pulmonary, 5085 (15.9%) were exclusively extrapulmonary, and 3071 (9.6%) were combined pulmonary and extrapulmonary. The percentages of tuberculosis cases that were exclusively extrapulmonary differed by lineage: East Asian, 13.0%; Euro-American, 13.8%; Indo-Oceanic, 22.6%; and East-African Indian, 34.3%. Compared with East Asian lineage, the odds of exclusively extrapulmonary tuberculosis relative to exclusively pulmonary tuberculosis were greater for Euro-American (adjusted OR, 1.3; 95% confidence interval [CI], 1.1–1.4), Indo-Oceanic (adjusted OR, 1.7; 95% CI, 1.5–1.9), and East-African Indian (adjusted OR, 1.6; 95% CI, 1.4–1.9) lineages. Conclusions. Phylogenetic lineage of M. tuberculosis is associated with the site of tuberculosis disease.

1 October 2007 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GMGerald H. Mazurek
Gerald H. Mazurek
SWStephen E. Weis
Stephen E. Weis
PMPatrick K. Moonan
Patrick K. Moonan
CDCharles L. Daley
Charles L. Daley
JBJohn Bernardo
John Bernardo
PLPhilip A. LoBue
Philip A. LoBue
Background. Interferon-γ release assays (IGRAs) are attractive alternatives to the tuberculin skin test (TST) for detecting Mycobacterium tuberculosi

1 November 2005 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
HSHomayoun Shams
Homayoun Shams
SWStephen E. Weis
Stephen E. Weis
PKPeter Klucar
Peter Klucar
ALAjit Lalvani
Ajit Lalvani
PMPatrick K. Moonan
Patrick K. Moonan
PBPeter F. Barnes
Peter F. Barnes
Rationale: Diagnosis of latent tuberculosis infection (LTBI) is currently based on the tuberculin skin test. The enzyme-linked immunospot assay (ELISPOT) is a new blood test to diagnose LTBI. Objective: To compare the ELISPOT and the tuberculin skin test for detecting LTBI in contacts of patients with tuberculosis. Methods: Prospective study of 413 contacts of patients with tuberculosis. Measurements and Main Results: Because there is no gold standard for LTBI, the sensitivity and specificity of the ELISPOT and tuberculin skin test cannot be directly measured. For each contact, we therefore estimated the likelihood of having LTBI by calculating a contact score that quantified exposure to and infectiousness of the index case. We analyzed the relationship of contact score to ELISPOT and tuberculin skin test results. The likelihood of a positive ELISPOT (p = 0.0005) and a tuberculin skin test (p = 0.01) increased significantly with rising contact scores. The contact score was more strongly related to the ELISPOT than to the tuberculin skin test results, although this difference was not statistically significant. Among U.S.-born persons and those who were not vaccinated with bacille Calmette-Guérin, approximately 30% had positive ELISPOT or tuberculin skin test results. Foreign-born, bacille Calmette-Guérin–vaccinated persons were significantly more likely to have a positive tuberculin skin test than a positive ELISPOT result (p < 0.0001). Conclusions: Compared with the tuberculin skin test, the ELISPOT appears to be at least as sensitive for diagnosis of LTBI in contacts of patients with tuberculosis.

1 August 2004 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
HSHomayoun Shams
Homayoun Shams
PKPeter Klucar
Peter Klucar
SWSteven E Weis
Steven E Weis
ALAjit Lalvani
Ajit Lalvani
PMPatrick K. Moonan
Patrick K. Moonan
PBPeter F. Barnes
Peter F. Barnes
The secreted Mycobacterium tuberculosis 10-kDa culture filtrate protein (CFP)10 is a potent T cell Ag that is recognized by a high percentage of persons infected with M. tuberculosis. We determined the molecular basis for this widespread recognition by identifying and characterizing a 15-mer peptide, CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ T cells from persons expressing multiple MHC class II and class I molecules, respectively. CFP1071–85 contained at least two epitopes, one of 10 aa (peptide T1) and another of 9 aa (peptide T6). T1 was recognized by CD4+ cells in the context of DRB1*04, DR5*0101, and DQB1*03, and by CD8+ cells of A2+ donors. T6 elicited responses by CD4+ cells in the context of DRB1*04 and DQB1*03, and by CD8+ cells of B35+ donors. Deleting a single amino acid from the amino or carboxy terminus of either peptide markedly reduced IFN-γ production, suggesting that they are minimal epitopes for both CD4+ and CD8+ cells. As far as we are aware, these are the shortest microbial peptides that have been found to elicit responses by both T cell subpopulations. The capacity of CFP1071–85 to stimulate IFN-γ production and CTL activity by CD4+ and CD8+ cells from persons expressing a spectrum of MHC molecules suggests that this peptide is an excellent candidate for inclusion in a subunit antituberculosis vaccine.

26 January 2009 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
JOJohn E. Oeltmann
John E. Oeltmann
JKJ. Steve Kammerer
J. Steve Kammerer
EPEric S. Pevzner
Eric S. Pevzner
PMPatrick K. Moonan
Patrick K. Moonan
The annual tuberculosis (TB) incidence in the United States (4.6 cases per 100 000 people) is among the lowest in the world,1 and the number of TB cases reported in the United States in 2007 (13 293) was the lowest ever recorded.2 However, risk of TB continues to be higher among certain demographic groups, including ethnic minorities, immunocompromised people, those who have a history of homelessness, and foreign-born persons.3-6 The epidemiology of TB in the United States has been best summarized by Iseman7: “As the epidemic tide of tuberculosis recedes from the shores of America, small tidepools of disease remain behind: pools populated by immigrants, the elderly, and the immunocompromised.”